Stem Cell Therapy For Parkinson’s Disease – The Current Scenario
Stem cell therapy for Parkinson’s disease is currently still under study and research by scientists. There are many issues surrounding the study of stem cell therapy for Parkinson’s disease, including clinical and ethical issues. However, the reality when patients can resort to stem cell therapy for Parkinson’s disease may be near or years from now.
The famous celebrity with Parkinson’s disease Michael J. Fox was diagnosed with the illness some 20 years ago in 1991. After 20 years of living with this disease, he has lost 80% of his brain’s dopamine cells, which are the dopamine-producing neurons responsible for coordination and motor skills. He is probably one of the most outspoken advocates in the US and the world on research for stem cell therapy for Parkinson’s disease. Through his effort since 1998, the Michael J. Fox Foundation for Parkinson’s Research has donated $300 million to Parkinson’s research, making it the largest contributor of funding for Parkinson’s disease research globally.
The medical research on stem cell therapy for Parkinson’s disease generally focuses on identifying the specific stem cells or embryonic stem cells which can regenerate or repair the damaged dopamine-producing neurons. Australians scientists have made some breakthrough on successfully reprogramming embryonic stem cells which behave like dopamine-producing neurons. The missing link for stem cell therapy for Parkinson’s disease is the safety issues of these stem cells. Dr Lachlan Thomson, one of the contributing scientists involved in the research on stem cell therapy for Parkinson’s disease, said, ‘We have made some recent progress in that area by identifying novel molecules on the therapeutic cells that allow us to target them and essentially pull them out and purify them…I think that will really potentially be an important breakthrough on the road to clinical translation. I think once this safety issue is resolved we are really going to be much closer; and there is no reason to think it couldn’t happen within the next five to 10 years, and there’s no reason to think it couldn’t happen in Australia.’ (Please refer to the source of this news from News Medical)
Apparently the research on stem cell therapy for Parkinson’s disease, as with any other clinical research, has to pass through layers and layers of stipulated protocols as spelled out in the laws of the country and that takes considerable time also. Therefore, the availability of stem cell therapy for Parkinson’s disease through main stream medical facilities may still take years before it becomes a reality. For patients who are suffering from Parkinson’s disease in the end stage, the wait may not be soon enough to save the day.
Stem Cell Therapy For Parkinson’s Disease – My Father’s Success Story on Oral Stem Cell Therapy
My father is 81 years old (as at 2012) and has had symptoms of Parkinson’s disease since his early 40s. For the past few years, the tremor has been getting more severe and significant. When he exerts more energy or carries heavy things, his hands would shake more vigorously and he could not stop the shaking or tremor in this case. He is not and has never been on Parkinson’s medication. His Parkinson’s disease is probably classified as ‘mild’ or in the stage 2, possibly stage 3. He started taking Deer placenta stem cells in the form of oral enteric-coated capsule on 5th October 2012. After about one month, some time around the first week of November 2012, we observed the complete absence of tremor.
Though my father’s case was not under clinical observation or study while he was taking the oral deer placenta as stem cell therapy for Parkinson’s disease, there is no doubt that the current medical treatment or medication has yet to render the results we have seen on my father. Some day when the main stream medical practice finally offers the stem cell therapy for Parkinson’s disease, the cost will likely be on the high side. How costly will it be? No one can predict. But in all likelihood, it will cost the patient 5 figures out of the pocket.
As mentioned earlier many patients living with the deteriorating conditions or in the end stage of Parkinson’s disease may not have the time to wait for the complete clinical evidence of stem cell therapy for Parkinson’s disease. Even when the therapy is available, many may not be able to afford the hefty price. An alternative stem cell therapy for Parkinson’s disease worth considering is the oral placenta of Deer stem cells available today.